Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix-Reference-Cited by-同舟云学术

Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix

Published:2010-09-21 Issue:5 Volume:71 Page:445-452
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Rozsa Bernadett,Nadji Mehrdad,Schally Andrew V.,Dezso Balazs,Flasko Tibor,Toth Gyorgy,Mile Melinda,Block Norman L.,Halmos Gabor

Publisher

Wiley

Subject

Urology,Oncology

Reference27 articles.

1. Benign prostatic hyperplasia;Webber;Clin Evid,2006

2. Molecular and cellular pathogenesis of benign prostatic hyperplasia;Lee;J Urol,2004

3. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia;Lepor;Rev Urol,2004

4. Benign prostatic hyperplasia: A review of its histogenesis and natural history;Oesterling;Prostate Suppl,1996

5. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention;Isaacs;Prostate Suppl,1990

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early investigational agents for the treatment of benign prostatic hyperplasia’;Expert Opinion on Investigational Drugs;2024-03-04

2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022;European Urology;2023-03

3. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates;International Journal of Molecular Sciences;2022-05-03

4. Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer;Molecules;2021-02-26

5. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate;World Journal of Urology;2019-09-10